ライフサイエンスコーパス: pulmonary arterial pressure

1 tion of inspired oxygen, shunt fraction, and pulmonary arterial pressure.

2 xygenation without a significant decrease in pulmonary arterial pressure.

3 was induced until doubling of baseline mean pulmonary arterial pressure.

4 se and other states associated with elevated pulmonary arterial pressure.

5 xia appear to contribute, including elevated pulmonary arterial pressure.

6 lmonary vascular remodeling, and the rise of pulmonary arterial pressure.

7 Mean pulmonary arterial pressure.

8 pulmonary capillary wedge pressure and mean pulmonary arterial pressure.

9 ; 40 ppm in 21% O(2) ), to selectively lower pulmonary arterial pressure.

10 ally in the presence of chronic elevation of pulmonary arterial pressures.

11 ks, significant decreases were noted in mean pulmonary arterial pressure (-10%) and in pulmonary vasc

12 od flow [Qs] of 2.0 +/- 0.7) and normal mean pulmonary arterial pressure (13.4 +/- 3.1 mm Hg).

13 at pre-stage II evaluation, including higher pulmonary arterial pressures (15.4+/-3.0 versus 14.5+/-3

14 ressure (10+/-4 versus 6+/-3 mm Hg; P=0.02), pulmonary arterial pressure (22+/-8 versus 11+/-4 mm Hg;

15 When applying the prior, mean pulmonary arterial pressure 25 mm Hg (PH(25)) cutoff, a

16 received simvastatin from Day 5 to 35 (mean pulmonary arterial pressure = 27 +/- 3 mm Hg, RV/LV+S =

17 s and right ventricular workload by lowering pulmonary arterial pressure (29.6 +/- 1.3 vs. 24.6 +/- 1

18 ations included 79+/-9% (mean+/-SEM) rise in pulmonary arterial pressure, 30+/-7% decline in cardiac

19 improvements in hemodynamic variables (mean pulmonary arterial pressure: 40 +/- 12 mm Hg vs. 33 +/-

20 an-European study, 91 patients with PH (mean pulmonary arterial pressure 46+/-15 mm Hg) underwent cli

21 y [85 female; mean age 53.6 12.5 years; mean pulmonary arterial pressure 46.6 15.1 mmHg; World Health

22 , rats that received vehicle had higher mean pulmonary arterial pressures (53 +/- 2 mm Hg) and right

23 ary circulation, terlipressin decreased mean pulmonary arterial pressure (-6.5 +/- 1.8 mm Hg; p = 0.0

24 put (-3,327 +/- 451 mL; p = 0.005), and mean pulmonary arterial pressure (-7 +/- 1 mm Hg; p < 0.001)

25 PTT, FWHM, and TTP were associated with mean pulmonary arterial pressure and cardiac index.

26 ertension (PAH) is characterized by elevated pulmonary arterial pressure and carries a very poor prog

27 ve pulmonary vasodilator, leading to reduced pulmonary arterial pressure and improved ventilation/per

28 via the suppression of the acute increase in pulmonary arterial pressure and improvement of right ven

29 nstrate that SB525334 significantly reverses pulmonary arterial pressure and inhibits right ventricul

30 Hypothermic CPB increased both mean pulmonary arterial pressure and left pulmonary vascular

31 mice was associated with a reduction in mean pulmonary arterial pressure and pulmonary vascular resis

32 ivity, and cGMP levels and partially restore pulmonary arterial pressure and pulmonary vascular resis

33 nitric-oxide synthase (eNOS) have increased pulmonary arterial pressure and pulmonary vascular resis

34 vector encoding the eNOS gene (AdCMVeNOS) on pulmonary arterial pressure and pulmonary vascular resis

35 Marked reductions in pulmonary arterial pressure and pulmonary vascular resis

36 sed, and there was a small reduction in mean pulmonary arterial pressure and pulmonary vascular resis

37 Their mean pulmonary arterial pressure and pulmonary vascular resis

38 hypoxemia with a pronounced increase in mean pulmonary arterial pressure and pulmonary vascular resis

39 mia but caused significant increases in mean pulmonary arterial pressure and pulmonary vascular resis

40 ad superior RV function despite similar mean pulmonary arterial pressure and pulmonary vascular resis

41 ascular afterload can be estimated from mean pulmonary arterial pressure and pulmonary vascular resis

42 e hemodynamic impairment, with a median mean pulmonary arterial pressure and pulmonary vascular resis

43 d results in an additive favorable effect on pulmonary arterial pressure and pulmonary vascular resis

44 1, and 0.3 mg x kg(-1) x h(-1)) reduced mean pulmonary arterial pressure and pulmonary vascular resis

45 We conclude that iron availability modifies pulmonary arterial pressure and pulmonary vascular respo

46 lumen and contribute to the elevation of the pulmonary arterial pressure and reduce local lung tissue

47 , and angio-obliteration leading to elevated pulmonary arterial pressure and resistance, right ventri

48 ary vascular remodeling, leading to elevated pulmonary arterial pressure and right heart hypertrophy.

49 Endotoxin caused an increase in pulmonary arterial pressure and right ventricular volume

50 Pasco, Peru), a setting that increases both pulmonary arterial pressure and sympathetic outflow.

51 ne whether varying iron availability affects pulmonary arterial pressure and the pulmonary vascular r

52 HIMF increased pulmonary arterial pressure and vascular resistance more

53 rtension (PPH) is characterized by increased pulmonary arterial pressure and vascular resistance.

54 lth and disease, including associations with pulmonary arterial pressure, and adverse neurological se

55 ean arterial pressure (MAP), cardiac output, pulmonary arterial pressure, and calculated pulmonary an

56 surement of mean systemic arterial pressure, pulmonary arterial pressure, and cardiac output.

57 nts of Ex-PHT are male sex, resting systolic pulmonary arterial pressure, and exercise parameters of

58 al caveolin-1-TRPV4 channel signaling lowers pulmonary arterial pressure, and impairment of endotheli

59 ent for recipient age, body mass index, mean pulmonary arterial pressure, and pretransplant diagnosis

60 PAOP, mean pulmonary arterial pressure, and pulmonary capillary pre

61 In controls subjects, right atrial pressure, pulmonary arterial pressure, and pulmonary capillary wed

62 ignificant improvement in exercise capacity, pulmonary arterial pressure, and quality of life.

63 g right ventricle systolic pressure and mean pulmonary arterial pressure, and restoring BMPR2 express

64 eases (<10 percent) in systemic arterial and pulmonary arterial pressures, and it had no effect on pu

65 t, oxygen delivery [DO2]), mean systemic and pulmonary arterial pressures, and the oxygenation index

66 lling pressure and the resultant increase in pulmonary arterial pressure are associated with disrupti

67 hypertrophy, restoring right ventricular and pulmonary arterial pressures, as well as the pulmonary v

68 ide animals showed a significant increase in pulmonary arterial pressure at 30 mins (47.5 +/- 2.4 and

69 changes in thrombospondin-2 associated with pulmonary arterial pressure at disease onset.

70 ndary end points comprised cardiac index and pulmonary arterial pressure at rest and during exercise

71 oppler estimates and invasive measurement of pulmonary arterial pressure at rest and peak exercise we

72 ventilation, ventilation-perfusion matching, pulmonary arterial pressure, basal airway tone, and resp

73 id regurgitation velocity-time integral, and pulmonary arterial pressure between patients with and wi

74 Pulmonary ventilation and pulmonary arterial pressure both rise progressively duri

75 ean right atrial pressure by 12 +/- 3%, mean pulmonary arterial pressure by 13 +/- 2%, and pulmonary

76 g vasculature, dose-dependently reducing the pulmonary arterial pressure by as much as 9 mmHg with no

77 used significant decreases in total Hb, mean pulmonary arterial pressure, cardiac index and systemic

78 rch infusion was accompanied by increases of pulmonary arterial pressure, cardiac index, and blood ox

79 Heart rate, mean arterial pressure, pulmonary arterial pressure, central venous pressure, ka

80 chi(2), 28.8; P=0.003) and exercise systolic pulmonary arterial pressure (chi(2), 40.1; P=0.002) and

81 nals, echocardiographic measures of systolic pulmonary arterial pressure correlated reasonably well w

82 pressure of at least 10 mm Hg with the mean pulmonary arterial pressure decreasing to 40 mm Hg or be

83 Increased pulmonary arterial pressure did not affect arterial oxyg

84 ata exist regarding its accuracy to estimate pulmonary arterial pressure during exercise.

85 ypoxic inspired air (FiO(2) = 12.5%) reduced pulmonary arterial pressure during sub-maximal cycling e

86 p had significantly higher mean systemic and pulmonary arterial pressures during resuscitation in com

87 Pulmonary embolism increased mean pulmonary arterial pressure from 15 4 to 33 6 mm Hg (p =

88 DCLHb raised systemic and pulmonary arterial pressures from baseline values of 83

89 sociated with HSA, which raised systemic and pulmonary arterial pressures from baseline values of 86

90 Pulmonary arterial pressure >/=15 mm Hg was 90% specific

91 zation to confirm the diagnosis of PAH (mean pulmonary arterial pressure >/=25 mm Hg and pulmonary ca

92 ypertension (PH), recently redefined as mean pulmonary arterial pressure >20 mm Hg (PH(20)), may be o

93 rogeneous population of patients with a mean pulmonary arterial pressure >20 mm Hg.

94 namics consistent with POPH (defined as mean pulmonary arterial pressure >25 mm Hg and pulmonary vasc

95 with secondary pulmonary hypertension (rest pulmonary arterial pressure >25 mm Hg).

96 ng PHT and Ex-PHT were defined as a systolic pulmonary arterial pressure >50 and >60 mm Hg, respectiv

97 When applying the prior, mean pulmonary arterial pressure >=25 mm Hg (PH(25)) cutoff,

98 By 2 hrs, pulmonary arterial pressure had decreased but was still

99 on and, with the exception of an increase in pulmonary arterial pressure, had no adverse effects on h

100 ard ratio, 1.09; P=0.027), exercise systolic pulmonary arterial pressure (hazard ratio, 1.03; P<0.001

101 , 5.2; 95% CI, 1.8-14.8; P = 0.002) and mean pulmonary arterial pressure (hazard ratio, 1.04; 95% CI,

102 Mild idiopathic pulmonary arterial pressure impairs LV diastolic complia

103 oxic challenge produced similar increases in pulmonary arterial pressure in both groups.

104 Iron deficiency augments hypoxic pulmonary arterial pressure in healthy individuals and e

105 Reduced pulmonary arterial pressure in MGCD0103-treated animals

106 tion of AdRSVeNOS attenuated the increase in pulmonary arterial pressure in mice exposed to the fibro

107 V4 channel signaling contributes to elevated pulmonary arterial pressure in PH.

108 nt strategies for restoring vasodilation and pulmonary arterial pressure in PH.

109 oad was primarily mediated by decreased mean pulmonary arterial pressure in the BPA group, while incr

110 y baroreceptors is obtained at physiological pulmonary arterial pressures in intact animals.

111 Pulmonary arterial pressure increased after hemoglobin i

112 Mean pulmonary arterial pressure increased relative to baseli

113 Pulmonary arterial pressure increases proportionally to

114 The increase in pulmonary arterial pressure induced in shunt lambs was g

115 efore, we investigated whether reductions in pulmonary arterial pressure influenced sympathetic outfl

116 Acute increases in PaO2, decreases in mean pulmonary arterial pressure, intensity of mechanical ven

117 O(2) (pO(2))] elicits signaling to regulate pulmonary arterial pressure is incompletely understood.

118 In humans, pulmonary arterial pressure is positively related to bas

119 tested the hypotheses that (1) elevated mean pulmonary arterial pressure is the most important hemody

120 s model, we found that the acute increase in pulmonary arterial pressure leading to right ventricle f

121 e and noninvasive), central venous pressure, pulmonary arterial pressure, left and right atrial press

122 arge body mass index, preoperative increased pulmonary arterial pressure, low stroke volume index, hy

123 ental approach, we demonstrate that reducing pulmonary arterial pressure lowers basal MSNA in healthy

124 ts with tricuspid regurgitation grade >2 and pulmonary arterial pressure <50 mm Hg.

125 ry arteries, leads to sustained elevation of pulmonary arterial pressure (mean >25 mm Hg at rest or >

126 Mean pulmonary arterial pressure, mean left atrial pressure,

127 el TGF-B ligand trap pharmacotherapy, remote pulmonary arterial pressure monitoring, next-generation

128 The compound reduced pulmonary arterial pressure more dramatically than tadal

129 death, mean systemic pressure (mSP) and mean pulmonary arterial pressure (mPA) emerged as the most im

130 ts: Pulmonary hypertension defined by a mean pulmonary arterial pressure (mPAP) >20 mm Hg was identif

131 ons between biventricular MPRI and both mean pulmonary arterial pressure (mPAP) (RV MPRI: rho = -0.59

132 he effects of sevoflurane inhalation on mean pulmonary arterial pressure (mPAP) and pulmonary vascula

133 ptolide-treated rats demonstrated lower mean pulmonary arterial pressure (mPAP) than vehicle-treated

134 ary hypertension (PH) is diagnosed by a mean pulmonary arterial pressure (mPAP) value of at least 25

135 heal instillation of liposomal fasudil, mean pulmonary arterial pressure (MPAP) was reduced by 37.6+/

136 RI metrics that showed correlation with mean pulmonary arterial pressure (mPAP) were used to create a

137 L-NAME resulted in a larger increase in mean pulmonary arterial pressure (MPAP) when compared with sa

138 used a marked and sustained decrease in mean pulmonary arterial pressure (MPAP), it also decreased me

139 unctional class (WHO FC); and change in mean pulmonary arterial pressure (mPAP), pulmonary vascular r

140 e, pulmonary artery occlusion pressure, mean pulmonary arterial pressure (MPAP), systemic vascular re

141 able to produce precise measurements of mean pulmonary arterial pressure (mPAP).

142 tively analyzed; 1593 patients with PH (mean pulmonary arterial pressure [mPAP], 43 mmHg +/- 13 [SD])

143 (odds ratio, 4.3; P=0.002), resting systolic pulmonary arterial pressure (odds ratio, 1.16; P=0.002),

144 (odds ratio 1.60, 95% CI 1.09 to 2.32), mean pulmonary arterial pressure of > or = 20 mm Hg (odds rat

145 progressively to 50 mL/kg/min, maintaining a pulmonary arterial pressure of < 25 mm Hg and a left atr

146 e is generally defined as a decrease in mean pulmonary arterial pressure of at least 10 mm Hg with th

147 acterized by a progressive elevation in mean pulmonary arterial pressure, often leading to right vent

148 There was no significant difference in pulmonary arterial pressure or systemic arterial pressur

149 ), with no changes in right atrial pressure, pulmonary arterial pressure, or pulmonary resistance.

150 In group 1, increasing Fio2 lowered mean pulmonary arterial pressure (p < 0.0001) and pulmonary v

151 (p < 0.0001) and a two-fold increase in mean pulmonary arterial pressure (p < 0.0001) compared with b

152 Pulmonary embolism increased mean pulmonary arterial pressure (p < 0.0001), pulmonary vasc

153 , increased Pao(2) (p <.001), and lower mean pulmonary arterial pressure (p <.001).

154 is found ventricle classification (P=0.001), pulmonary arterial pressure (P</=0.001) annulus area (P=

155 most closely associated with increased mean pulmonary arterial pressure (P=0.016).

156 They also had increased pulmonary arterial pressures (P< .05) with elevated leve

157 ransposase showed a significant reduction in pulmonary arterial pressure (PABP, 31.67+/-6.03 mmHg, P<

158 variables were mean arterial pressure, mean pulmonary arterial pressure, PAOP, pulmonary capillary p

159 During normoxic conditions, mean pulmonary arterial pressure (PAP) and pulmonary to syste

160 Values of SPP were plotted against mean pulmonary arterial pressure (PAP) and sigmoid functions

161 RBCs from hypoxemic patients with elevated pulmonary arterial pressure (PAP) exhibit a similar FeNO

162 Physiological increases in pulmonary arterial pressure (PAP) induced significant in

163 Abnormal pulmonary arterial pressure (PAP) responses to exercise

164 luded mean right atrial pressure (RAP), mean pulmonary arterial pressure (PAP), cardiac index, transp

165 The increase in pulmonary arterial pressure (PAP), PVR, RVM, and pulmona

166 l signaling promotes vasodilation and lowers pulmonary arterial pressure (PAP).

167 of the sixty patients with COPD had PH (mean pulmonary arterial pressure [PAPm] >/= 25 mm Hg).

168 nous flow can occur when PA exceeds both the pulmonary arterial pressure (Ppa) and pulmonary venous p

169 , rats that received vehicle had higher mean pulmonary arterial pressures (Ppa = 41 +/- 3 mm Hg) (p <

170 ements (mean+/-SD, 8.3+/-2.8 per subject) of pulmonary arterial pressure, pulmonary arterial wedge pr

171 Cardiac output, pulmonary arterial pressure, pulmonary artery occlusion

172 crolimus pretreatment prevented increases in pulmonary arterial pressure, pulmonary vascular resistan

173 Sildenafil reduced exercise pulmonary arterial pressure, pulmonary vascular resistan

174 amic variables (cardiac output, systemic and pulmonary arterial pressures, pulmonary artery occlusion

175 with wedge pressure (r = 0.93, P < .001) and pulmonary arterial pressure (r = 0.93, P < .002).

176 Pulmonary arterial pressure (r=0.66), annulus area (r=0.

177 groups 2 to 4, hemodynamic functions (except pulmonary arterial pressure) recovered, yet neither tota

178 usion resulted in a greater increase in mean pulmonary arterial pressure relative to cardiac output i

179 Elevation of pulmonary arterial pressure resets the vasomotor limb of

180 alues, and 6%, 16%, 23%, and 23% in the mean pulmonary arterial pressure, respectively.

181 f statin therapy in the improvement of 6MWD, pulmonary arterial pressure, right atrial pressure, card

182 These variables included mean pulmonary arterial pressure, right ventricular total pow

183 lding and occlusion, leading to the elevated pulmonary arterial pressures, right ventricular hypertro

184 With exercise, the mean pulmonary arterial pressure rose from 36+/-12 to 52+/-10

185 The liposome-induced rises of pulmonary arterial pressure showed close quantitative an

186 ood was allowed to drain into a reservoir as pulmonary arterial pressure started to rise after veratr

187 Pulmonary capillary wedge pressure, pulmonary arterial pressure, stroke volume, and cardiac

188 Sildenafil reduced resting pulmonary arterial pressure, systemic vascular resistanc

189 An increase in pulmonary arterial pressure that is not due to coexisten

190 er that, in those with normal or near-normal pulmonary arterial pressures, the pulsatile component of

191 intravenously administered to increase mean pulmonary arterial pressure to 35 mm Hg.

192 pulmonary capillary wedge pressure and mean pulmonary arterial pressure to volume loading with rapid

193 In patients with grade A TR signals, mean pulmonary arterial pressure-to-workload ratio at a thres

194 a steady reduction of right ventricular and pulmonary arterial pressures, toward normal levels of ri

195 in endothelial cell caveolae maintain a low pulmonary arterial pressure under normal conditions.

196 H based on QRS-gated DPD demonstrated higher pulmonary arterial pressures versus isolated postcapilla

197 Peak pulmonary arterial pressure was higher after resuscitati

198 Pulmonary arterial pressure was increased during sepsis

199 Mean pulmonary arterial pressure was significantly higher aft

200 An increase in pulmonary arterial pressure was the only observed hemody

201 Mean pulmonary arterial pressure was unchanged.

202 le pressures designed to simulate the normal pulmonary arterial pressure waveform.

203 ate, mean transmitral gradient, and systolic pulmonary arterial pressure were assessed at different s

204 Aortic blood flow, Pao(2), and pulmonary arterial pressure were measured 4 wks later.

205 nnular plane systolic excursion and systolic pulmonary arterial pressure were measured at rest and du

206 for 10 minutes), and LAP, systemic flow, and pulmonary arterial pressure were measured in both fixed

207 PVR and mean pulmonary arterial pressure were not significant predict

208 Mean pulmonary arterial pressures were comparable (46+/-4 and

209 , in turn, may play a key role in increasing pulmonary arterial pressure, which is involved in the de

210 ikewise, none of the other indices including pulmonary arterial pressure (WMD: -0.97 mmHg, 95%CI: -4.